Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis

Toufik Mahfood Haddad, Shadi Hamdeh, Arun Kanmanthareddy, Venkata (Mahesh) Alla

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: Numerous studies have assessed the association between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). However, results have been conflicting due to variability in definitions of NAFLD and ascertainment of CVD, often combining clinical and surrogate endpoints. We therefore systematically reviewed published literature to assess the association between NAFLD and clinical cardiovascular events (CVE) and performed a meta-analysis. Methods: We searched PubMed, Medline, Cochrane, CINAHL, and Web of Science databases using terms "nonalcoholic fatty liver disease", "nonalcoholic steatohepatitis", "cardiovascular disease", and their combinations to identify prospective studies published from inception through March 2016. Data from selected studies was extracted and meta-analysis was then performed using random effects model. Results: A total of six studies with 25,837 patients (NAFLD: 5953; controls: 19,884) were included in the final analysis. Patients with NAFLD had a significantly higher risk of clinical CVE compared to controls (RR: 1.77; 95% CI: 1.26-2.48, p. <. 0.001). Exclusion sensitivity analysis did not alter the above results. The association remained consistent for subgroups with clinical coronary artery disease (RR: 2.26; 95% CI: 1.04-4.92, p. <. 0.001) and ischemic stroke (RR: 2.09; 95% CI: 1.46-2.98, p. <. 0.001). The risk of cardiovascular mortality was also increased in the NAFLD group (RR 1.46, 95% CI 1.31-1.64, p. <. 0.001). Conclusion: NAFLD patients have a significantly higher risk for clinical CVE compared to those without. These results need to be confirmed in large prospective studies.

Original languageEnglish (US)
JournalDiabetes and Metabolic Syndrome: Clinical Research and Reviews
DOIs
StateAccepted/In press - Nov 7 2016

Fingerprint

Meta-Analysis
Cardiovascular Diseases
Prospective Studies
Non-alcoholic Fatty Liver Disease
PubMed
Coronary Artery Disease
Biomarkers
Stroke
Databases
Mortality

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{14795a9f1d874ebdab3586223eedc96e,
title = "Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis",
abstract = "Objective: Numerous studies have assessed the association between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). However, results have been conflicting due to variability in definitions of NAFLD and ascertainment of CVD, often combining clinical and surrogate endpoints. We therefore systematically reviewed published literature to assess the association between NAFLD and clinical cardiovascular events (CVE) and performed a meta-analysis. Methods: We searched PubMed, Medline, Cochrane, CINAHL, and Web of Science databases using terms {"}nonalcoholic fatty liver disease{"}, {"}nonalcoholic steatohepatitis{"}, {"}cardiovascular disease{"}, and their combinations to identify prospective studies published from inception through March 2016. Data from selected studies was extracted and meta-analysis was then performed using random effects model. Results: A total of six studies with 25,837 patients (NAFLD: 5953; controls: 19,884) were included in the final analysis. Patients with NAFLD had a significantly higher risk of clinical CVE compared to controls (RR: 1.77; 95{\%} CI: 1.26-2.48, p. <. 0.001). Exclusion sensitivity analysis did not alter the above results. The association remained consistent for subgroups with clinical coronary artery disease (RR: 2.26; 95{\%} CI: 1.04-4.92, p. <. 0.001) and ischemic stroke (RR: 2.09; 95{\%} CI: 1.46-2.98, p. <. 0.001). The risk of cardiovascular mortality was also increased in the NAFLD group (RR 1.46, 95{\%} CI 1.31-1.64, p. <. 0.001). Conclusion: NAFLD patients have a significantly higher risk for clinical CVE compared to those without. These results need to be confirmed in large prospective studies.",
author = "{Mahfood Haddad}, Toufik and Shadi Hamdeh and Arun Kanmanthareddy and Alla, {Venkata (Mahesh)}",
year = "2016",
month = "11",
day = "7",
doi = "10.1016/j.dsx.2016.12.033",
language = "English (US)",
journal = "Diabetes and Metabolic Syndrome: Clinical Research and Reviews",
issn = "1871-4021",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events

T2 - A systematic review and meta-analysis

AU - Mahfood Haddad, Toufik

AU - Hamdeh, Shadi

AU - Kanmanthareddy, Arun

AU - Alla, Venkata (Mahesh)

PY - 2016/11/7

Y1 - 2016/11/7

N2 - Objective: Numerous studies have assessed the association between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). However, results have been conflicting due to variability in definitions of NAFLD and ascertainment of CVD, often combining clinical and surrogate endpoints. We therefore systematically reviewed published literature to assess the association between NAFLD and clinical cardiovascular events (CVE) and performed a meta-analysis. Methods: We searched PubMed, Medline, Cochrane, CINAHL, and Web of Science databases using terms "nonalcoholic fatty liver disease", "nonalcoholic steatohepatitis", "cardiovascular disease", and their combinations to identify prospective studies published from inception through March 2016. Data from selected studies was extracted and meta-analysis was then performed using random effects model. Results: A total of six studies with 25,837 patients (NAFLD: 5953; controls: 19,884) were included in the final analysis. Patients with NAFLD had a significantly higher risk of clinical CVE compared to controls (RR: 1.77; 95% CI: 1.26-2.48, p. <. 0.001). Exclusion sensitivity analysis did not alter the above results. The association remained consistent for subgroups with clinical coronary artery disease (RR: 2.26; 95% CI: 1.04-4.92, p. <. 0.001) and ischemic stroke (RR: 2.09; 95% CI: 1.46-2.98, p. <. 0.001). The risk of cardiovascular mortality was also increased in the NAFLD group (RR 1.46, 95% CI 1.31-1.64, p. <. 0.001). Conclusion: NAFLD patients have a significantly higher risk for clinical CVE compared to those without. These results need to be confirmed in large prospective studies.

AB - Objective: Numerous studies have assessed the association between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). However, results have been conflicting due to variability in definitions of NAFLD and ascertainment of CVD, often combining clinical and surrogate endpoints. We therefore systematically reviewed published literature to assess the association between NAFLD and clinical cardiovascular events (CVE) and performed a meta-analysis. Methods: We searched PubMed, Medline, Cochrane, CINAHL, and Web of Science databases using terms "nonalcoholic fatty liver disease", "nonalcoholic steatohepatitis", "cardiovascular disease", and their combinations to identify prospective studies published from inception through March 2016. Data from selected studies was extracted and meta-analysis was then performed using random effects model. Results: A total of six studies with 25,837 patients (NAFLD: 5953; controls: 19,884) were included in the final analysis. Patients with NAFLD had a significantly higher risk of clinical CVE compared to controls (RR: 1.77; 95% CI: 1.26-2.48, p. <. 0.001). Exclusion sensitivity analysis did not alter the above results. The association remained consistent for subgroups with clinical coronary artery disease (RR: 2.26; 95% CI: 1.04-4.92, p. <. 0.001) and ischemic stroke (RR: 2.09; 95% CI: 1.46-2.98, p. <. 0.001). The risk of cardiovascular mortality was also increased in the NAFLD group (RR 1.46, 95% CI 1.31-1.64, p. <. 0.001). Conclusion: NAFLD patients have a significantly higher risk for clinical CVE compared to those without. These results need to be confirmed in large prospective studies.

UR - http://www.scopus.com/inward/record.url?scp=85010653573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010653573&partnerID=8YFLogxK

U2 - 10.1016/j.dsx.2016.12.033

DO - 10.1016/j.dsx.2016.12.033

M3 - Article

C2 - 28017631

AN - SCOPUS:85010653573

JO - Diabetes and Metabolic Syndrome: Clinical Research and Reviews

JF - Diabetes and Metabolic Syndrome: Clinical Research and Reviews

SN - 1871-4021

ER -